Home Drug IndexClinical Monograph

Piperacillin + Tazobactam Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antibacterial

Subclass

Extended-spectrum penicillin + Beta-lactamase inhibitor combination

Speciality

Infectious Disease

Schedule (India)

Schedule H

Routes

Intravenous (IV)

Formulations

Form	Strengths (Piperacillin + Tazobactam)
Powder for IV Injection/Infusion	4 g + 500 mg (4.5 g vial)
Powder for IV Injection/Infusion	2 g + 250 mg (2.25 g vial)
Powder for IV Injection/Infusion	1 g + 125 mg (1.125 g vial) — limited availability

Reconstitution Note: Reconstitute with Sterile Water for Injection, Normal Saline, or 5% Dextrose. Administer as IV infusion over 30 minutes (standard) or 3–4 hours (extended infusion for severe infections).

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Nosocomial Pneumonia (Including Ventilator-Associated Pneumonia)

Adults:

Parameter	Recommendation
Starting dose	4.5 g IV every 8 hours
Titration	Increase frequency to every 6 hours for severe infections or high bacterial load
Usual maintenance dose	4.5 g IV every 6–8 hours
Maximum dose	4.5 g IV every 6 hours (18 g piperacillin/day)
Duration	7–14 days; guided by clinical response and cultures

Clinical Note: Combine with aminoglycoside or fluoroquinolone for suspected Pseudomonas aeruginosa infection. Not effective against MRSA — add vancomycin/linezolid if suspected.

2. Complicated Intra-Abdominal Infections (cIAI)

Adults:

Parameter	Recommendation
Starting dose	4.5 g IV every 8 hours
Titration	Increase to every 6 hours for severe peritonitis or sepsis
Usual maintenance dose	4.5 g IV every 6–8 hours
Maximum dose	4.5 g IV every 6 hours
Duration	4–7 days following adequate source control; extend if source control incomplete

Clinical Note: Provides coverage for gram-negative aerobes, gram-positive organisms, and anaerobes. Adequate surgical source control is essential.

3. Complicated Urinary Tract Infections (cUTI) / Pyelonephritis

Adults:

Parameter	Recommendation
Starting dose	4.5 g IV every 8 hours
Titration	Not routinely required
Usual maintenance dose	4.5 g IV every 8 hours
Maximum dose	4.5 g IV every 6 hours (in severe urosepsis)
Duration	7–14 days; step-down to oral therapy when clinically stable

4. Complicated Skin and Soft Tissue Infections (Including Diabetic Foot Infections)

Adults:

Parameter	Recommendation
Starting dose	4.5 g IV every 8 hours
Titration	Increase to every 6 hours for severe necrotising infections
Usual maintenance dose	4.5 g IV every 6–8 hours
Maximum dose	4.5 g IV every 6 hours
Duration	7–14 days for soft tissue infections; 2–4 weeks for osteomyelitis component in diabetic foot

Clinical Note: Add MRSA coverage (vancomycin/linezolid) if risk factors present. Surgical debridement critical for necrotising infections.

5. Febrile Neutropenia (Empirical Therapy in High-Risk Patients)

Adults:

Parameter	Recommendation
Starting dose	4.5 g IV every 6 hours
Titration	Not applicable
Usual maintenance dose	4.5 g IV every 6 hours
Maximum dose	4.5 g IV every 6 hours
Duration	Until neutrophil recovery (ANC >500/µL) and afebrile for ≥48 hours; minimum 7 days

Clinical Note: Preferred empirical monotherapy for febrile neutropenia per AIIMS and Tata Memorial protocols. Add aminoglycoside if septic shock or suspected resistant Pseudomonas. Add vancomycin if catheter-related infection or skin/soft tissue focus suspected.

6. Sepsis / Septic Shock (Empirical Therapy for Healthcare-Associated Infections)

Adults:

Parameter	Recommendation
Starting dose	4.5 g IV every 6 hours
Titration	Not applicable
Usual maintenance dose	4.5 g IV every 6 hours
Maximum dose	4.5 g IV every 6 hours
Duration	7–14 days; de-escalate based on culture results

Clinical Note: Appropriate for suspected gram-negative sepsis including ESBL-producers (if local susceptibility >90%). Consider extended infusion (4 hours) for severe sepsis to optimise pharmacodynamics.

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Severe Community-Acquired Pneumonia (CAP) requiring ICU admission	4.5 g IV every 6 hours	7–10 days	OFF-LABEL. Used when aspiration suspected or healthcare-associated risk factors present. Add macrolide for atypical coverage. Based on institutional protocols (AIIMS, PGI)
Pyelonephritis with suspected ESBL organisms	4.5 g IV every 8 hours	10–14 days	OFF-LABEL. Specialist use. Requires local antibiogram data showing susceptibility. Step-down to oral per culture
Cholangitis / Hepatobiliary Sepsis	4.5 g IV every 6–8 hours	7–10 days with source control	OFF-LABEL. Provides broad coverage including anaerobes. ERCP/drainage essential

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

1. Nosocomial Pneumonia / Complicated Intra-Abdominal Infections / Complicated Skin and Soft Tissue Infections

Weight-Based Dosing (≥2 months to <40 kg):

Parameter	Recommendation
Starting dose	80 mg/kg (piperacillin component) IV
Titration	May increase to 100 mg/kg/dose for severe infections
Usual maintenance dose	80–100 mg/kg (piperacillin component) every 6–8 hours
Maximum single dose	4 g piperacillin (4.5 g Pip-Tazo)
Maximum daily dose	16 g piperacillin/day (300–400 mg/kg/day)
Duration	As per indication; typically 7–14 days

Dosing Table by Weight:

5 kg	400–500 mg (Pip component)	Every 8 hours
10 kg	800–1000 mg (Pip component)	Every 8 hours
20 kg	1.6–2 g (Pip component)	Every 6–8 hours
30 kg	2.4–3 g (Pip component)	Every 6–8 hours
≥40 kg	Adult dosing (4.5 g)	Every 6–8 hours

2. Febrile Neutropenia (Empirical Therapy)

Children ≥2 months:

Parameter	Recommendation
Starting dose	80–100 mg/kg (piperacillin component) IV
Titration	Not applicable
Usual maintenance dose	80–100 mg/kg every 6 hours
Maximum single dose	4.5 g
Maximum daily dose	18 g piperacillin/day
Duration	Until ANC recovery and afebrile ≥48 hours

Clinical Note: Preferred empirical monotherapy for paediatric febrile neutropenia at major oncology centres. Add aminoglycoside if haemodynamically unstable.

3. Sepsis / Severe Bacterial Infections

Neonates (Specialist supervision mandatory):

Age	Dose (Piperacillin component)	Frequency
<7 days, <2 kg	50 mg/kg	Every 12 hours
<7 days, ≥2 kg	50 mg/kg	Every 8 hours
7–28 days, <2 kg	50 mg/kg	Every 8 hours
7–28 days, ≥2 kg	50 mg/kg	Every 6 hours

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Notes
Cystic Fibrosis Pulmonary Exacerbations	90–100 mg/kg (Pip component) every 6 hours	14–21 days	OFF-LABEL. Specialist only. Anti-pseudomonal coverage required. Maximum 18 g/day

Age Restrictions and Safety Monitoring

Age Group	Recommendation
<2 months	Not recommended except under specialist supervision in NICU setting
2 months–12 years	Weight-based dosing; requires paediatric infectious disease input for complex infections
≥12 years and ≥40 kg	Adult dosing appropriate

Safety Monitoring in Paediatrics:

Renal function monitoring (serum creatinine)
Electrolytes (particularly potassium)
CBC with differential if therapy >7 days
Signs of hypersensitivity or infusion reactions
Monitor IV site for phlebitis

Renal Adjustments

Dose adjustment required based on creatinine clearance:

CrCl (mL/min)	Dose Recommendation
>40	4.5 g IV every 6–8 hours (no adjustment)
20–40	4.5 g IV every 8 hours
<20	2.25 g IV every 8 hours
Haemodialysis	2.25 g IV every 8 hours + supplemental dose of 2.25 g after each dialysis session
CAPD	2.25 g IV every 12 hours
CRRT (CVVH/CVVHD/CVVHDF)	4.5 g IV every 8 hours (adjust based on effluent rate and clinical response)

Clinical Note: Calculate CrCl using Cockcroft-Gault formula. In elderly patients, serum creatinine may underestimate renal impairment.

Hepatic adjustment

Contraindications

Known hypersensitivity to piperacillin, tazobactam, or any penicillin
History of severe hypersensitivity reaction (anaphylaxis, angioedema) to any beta-lactam antibiotic (penicillins, cephalosporins, carbapenems)
History of cholestatic jaundice or hepatic dysfunction associated with piperacillin-tazobactam use

Cautions

History of non-severe penicillin or cephalosporin allergy — monitor closely for allergic reactions (cross-reactivity risk 1–2%)
Renal impairment — dose adjustment essential to prevent drug accumulation, neurotoxicity, and seizures
Pre-existing seizure disorder — high doses may lower seizure threshold; maintain appropriate dosing for renal function
Concurrent nephrotoxic agents (aminoglycosides, vancomycin, NSAIDs, amphotericin B) — monitor renal function closely
History of Clostridioides difficile infection or antibiotic-associated colitis
Sodium load — each 4.5 g vial contains approximately 216 mg (9.4 mEq) sodium; use cautiously in patients with heart failure, cirrhosis, or sodium restriction
Bleeding disorders or concurrent anticoagulation — may prolong bleeding time
Prolonged therapy (>14 days) — increased risk of superinfection, haematological abnormalities

Pregnancy

Parameter	Recommendation
Overall safety	Generally considered safe; widely used in pregnancy for severe infections
Risk category	Category B (US legacy); no formal India classification
Preferred alternatives	None required for severe infections; Pip-Tazo preferred when broad-spectrum IV coverage needed
When to use	Appropriate for serious infections including pyelonephritis, chorioamnionitis, postpartum sepsis
Monitoring	Maternal renal function, LFTs in prolonged courses; standard foetal monitoring

Lactation

Parameter	Recommendation
Compatibility	Compatible with breastfeeding
Drug levels in milk	Low; minimal systemic absorption by infant expected
Preferred alternatives	None required; acceptable during breastfeeding
Infant monitoring	Observe for loose stools, oral thrush, or rash; temporary GI disturbance possible but usually mild

Elderly

Parameter	Recommendation
Starting dose	4.5 g IV every 8 hours (if renal function normal)
Titration	Not applicable
Renal consideration	Calculate CrCl; age-related decline in renal function common even with normal serum creatinine; dose reduce per renal adjustment table
Specific risks	Increased susceptibility to nephrotoxicity, electrolyte disturbances (hypokalaemia), bleeding, and confusion/encephalopathy at higher doses
Monitoring	Renal function before and during therapy; electrolytes; signs of neurotoxicity

Major drug interactions

Drug	Interaction	Recommendation
Methotrexate	Reduced renal clearance of methotrexate → increased risk of haematological and GI toxicity	AVOID combination if possible; if essential, monitor methotrexate levels and CBC closely; consider leucovorin rescue
Probenecid	Inhibits tubular secretion → increased and prolonged piperacillin levels	Avoid concurrent use; if used together, monitor for toxicity
Neuromuscular blocking agents (Vecuronium, Rocuronium, Atracurium)	Prolonged neuromuscular blockade reported with aminopenicillins	Monitor neuromuscular function closely; may require dose adjustment of paralytic agent
Oral anticoagulants (Warfarin, Acenocoumarol)	Enhanced anticoagulant effect; mechanism includes vitamin K suppression via gut flora alteration	Monitor INR closely during and after Pip-Tazo course; adjust anticoagulant dose as needed

Moderate drug interactions

Drug	Interaction	Recommendation
Aminoglycosides (Amikacin, Gentamicin, Tobramycin)	Synergistic antibacterial effect but physical incompatibility if mixed; additive nephrotoxicity	Administer via separate IV lines; never mix in same bag; monitor renal function and aminoglycoside levels
Vancomycin	Increased risk of acute kidney injury when used in combination	Unidentified
Loop diuretics (Furosemide)	Potential increased nephrotoxicity	Monitor renal function; generally safe with hydration
Heparin	Potential additive effect on bleeding time	Monitor for bleeding; use standard coagulation monitoring
Phenytoin	Possible decreased phenytoin levels	Monitor phenytoin levels if used concurrently

Common Adverse effects

Diarrhoea (most frequent)
Nausea and vomiting
Skin rash (maculopapular)
Injection site reactions (phlebitis, pain)
Headache
Insomnia
Hypokalaemia
Transient elevation of liver enzymes (AST, ALT)
Fever
Positive direct Coombs test (without haemolysis)

Serious Adverse effects

Adverse Effect	Clinical Notes
Anaphylaxis	Rare; discontinue immediately; manage with adrenaline and supportive care
Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis	Very rare; discontinue immediately; requires hospitalisation
Clostridioides difficile-associated diarrhoea (CDAD)	May occur during or after therapy; discontinue Pip-Tazo if confirmed; treat with oral vancomycin or fidaxomicin
Acute interstitial nephritis	Presents with fever, rash, eosinophilia, rising creatinine; discontinue and consider corticosteroids
Haematological toxicity (Thrombocytopenia, Leucopenia, Neutropenia)	Usually with prolonged therapy (>14 days); monitor CBC weekly; typically reversible on discontinuation
Seizures	Risk increased with high doses, renal impairment, or pre-existing CNS disease; ensure appropriate dose adjustment
Coagulopathy	Vitamin K-dependent; more common with prolonged use or malnutrition; monitor PT/INR
Drug-induced liver injury	Rare; cholestatic pattern; monitor LFTs if symptomatic

Monitoring requirements

Phase	Parameters
Baseline	Serum creatinine, eGFR/CrCl, LFTs, CBC with differential, electrolytes (especially potassium), allergy history
During treatment (short course <7 days)	Renal function (every 2–3 days in ICU/high-risk patients); clinical response; signs of hypersensitivity
During treatment (≥7 days)	CBC weekly; LFTs weekly; renal function every 2–3 days; electrolytes (K+)
Prolonged therapy (>14 days)	As above + coagulation profile (PT/INR); watch for superinfection (oral thrush, C. difficile); neurotoxicity signs
If on concomitant nephrotoxins	Renal function daily or alternate days

Brands in India

Brand Name	Manufacturer
Tazact	Cipla
Pipzo	Dr. Reddy's
Zosyn	Pfizer
Piptaz	Aristo
Tazopen	Alkem
Pipracil Plus	Lupin
Tazofast	Hetero
Piperacillin + Tazobactam (Generic)	Multiple manufacturers

Government/Jan Aushadhi Supply: Available under generic names at subsidised rates

Price range (INR)

Formulation	Approximate Price
4.5 g vial (Private brands)	₹150–₹350
4.5 g vial (Jan Aushadhi/Government supply)	₹50–₹100
2.25 g vial (Private brands)	₹80–₹180
2.25 g vial (Jan Aushadhi/Government supply)	₹30–₹60

Regulatory Note: Listed under NLEM 2022. NPPA price-controlled for scheduled formulations. Available through government hospital pharmacies and Jan Aushadhi kendras.

Clinical pearls

Extended infusion strategy: For severe infections (sepsis, VAP, febrile neutropenia), administer each dose over 3–4 hours instead of standard 30 minutes. This optimises time above MIC and improves pharmacodynamic outcomes. Widely adopted in Indian ICUs.
Spectrum limitations: Pip-Tazo does NOT cover MRSA, VRE, carbapenem-resistant Enterobacteriaceae (CRE), or Stenotrophomonas maltophilia. Add appropriate agents if these are suspected.
ESBL coverage caveat: Effective against many ESBL-producing organisms, but MIC creep reported. Use only if local antibiogram shows susceptibility >90%. Carbapenems preferred for serious ESBL infections with sepsis.
Sodium load awareness: Each 4.5 g vial contains ~9.4 mEq sodium. In patients receiving every-6-hour dosing, daily sodium from Pip-Tazo alone exceeds 37 mEq. Adjust total sodium intake in heart failure and cirrhosis.
De-escalation imperative: Pip-Tazo is a broad-spectrum reserve antibiotic. Always review cultures at 48–72 hours and de-escalate to narrower-spectrum agent when susceptibilities available. This aligns with ICMR AMR stewardship recommendations.
Vancomycin combination nephrotoxicity: Recent evidence shows increased AKI risk with Pip-Tazo + Vancomycin compared to other beta-lactam + vancomycin combinations. Use with close renal monitoring and consider alternatives if renal function declines.

Version

RxIndia v1.0 — 30 Apr 2025

Reference

CDSCO Drug Database and Product Inserts
Indian Pharmacopoeia 2022
National List of Essential Medicines (NLEM) 2022
API Textbook of Medicine (11th Edition)
AIIMS Antimicrobial Guidelines 2022
ICMR Treatment Guidelines for Antimicrobial Use in Common Syndromes (2019)
ICMR Antimicrobial Resistance Surveillance Network Reports
Tata Memorial Hospital Febrile Neutropenia Protocols
IAP Guidelines for Paediatric Antimicrobial Use
Harrison's Principles of Internal Medicine (21st Edition)
Goodman & Gilman's The Pharmacological Basis of Therapeutics

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...